# ATTACC (NCT04972110)

> Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04972110
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Repare Therapeutics
- Conditions: Advanced Solid Tumor, Adult
- Interventions: RP-3500 (camonsertib)
- Enrollment: 156
- Primary outcome: Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid Tumors
- Primary outcome: Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid Tumors

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=attacc-nct04972110